BCO vs CRSP Comparison

The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.